Enrolling by Invitation
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
NCT07312578
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
- Locations
-
- Department of GI Oncology, Peking University Cancer Hospital, Beijing, Beijing Municipality, China